Mehta 2003

Methods	RCT: enrolled: not reported evaluated: 401
Participants	Inclusion: 1. MRI demonstrated brain metastases 2. histologically proven solid tumours 3. required WBRT 4. KPS of at least 70 Exclusion: 1. small cell lung cancer, lymphoma or germ‐cell tumors 2. brain metastases partially or completely resected 3. received prior cranial irradiation 4. leptomeningeal metastases 5. two or more sites of extracranial metastases except when breast was the primary cancer 6. chemotherapy planned during WBRT
Interventions	WBRT (3000 cGy/10 fr and motexafin gadolinium vs WBRT (3000 cGy/10 fr)
Outcomes	1. Survival 2. Neurologic progression
Notes	QS = 2